Transactions
May 2, 2007
In MedImmune Acquisition, an Old Hand Helps Perpetuate a Hot Trend
Deals Column - By Jason Song - Take an underperforming company with a plethora of promising new drugs, mix in a ravenous appetite for biotechnology firms, throw in a cagey old corporate raider, and you've got last week's biggest deal: AstraZeneca's announced purchase of MedImmune Inc. for $15.6 billion.
By Jason Song
Take an underperforming company with a plethora of promising new drugs, mix in a ravenous appetite for biotechnology firms, throw in a cagey old corporate raider, and you've got last week's biggest deal: AstraZeneca's announced purchase of MedImmune Inc. for $15.6 billion.
The all-cash acquisition is the largest transaction to date for an American biotech compan...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In